How to Help Your Patients Save Money on Givlaari: A Provider's Guide to Savings Programs

Givlaari's list price of approximately $575,000 per year makes it one of the most expensive medications your patients will ever be prescribed. For clinicians managing acute hepatic porphyria (AHP), navigating this cost landscape is not optional — it is a clinical responsibility. Patients who cannot afford the medication or whose insurance denies coverage will not receive treatment, and untreated AHP attacks can cause hospitalizations, permanent nerve damage, and death.

This guide gives you a complete picture of every financial assistance pathway available for Givlaari patients — and how to direct your patients to the right one based on their insurance status.

Understanding the Givlaari Cost Structure

Givlaari is priced at approximately $39,000 per single-dose vial. Since dosing is weight-based (2.5 mg/kg once monthly) and vials are 189 mg/mL in a 1-mL vial, a single vial typically covers one monthly dose for most patients. This translates to an annual list price of approximately $575,000.

After mandatory government rebates and discounts, Alnylam has reported net revenue per patient that is significantly lower — approximately $442,000 annually — but even with insurer negotiated rates, the cost burden is substantial. For most commercially insured patients, the medication will be at the highest specialty tier with the most significant cost sharing — without financial assistance, out-of-pocket costs could easily reach $5,000-$20,000 or more per year.

Alnylam Assist® Commercial Copay Program

The Alnylam Assist® Commercial Copay Program is the first-line financial assistance resource for commercially insured patients. Key points for providers:

• Who qualifies: Patients with commercial (private/employer) insurance. Not applicable to Medicare, Medicaid, or other government-sponsored insurance.
• How to enroll: Include the patient in the Givlaari Start Form submission. Alnylam Assist® will assess eligibility during the onboarding process.
• Coverage note: This program covers drug costs but does NOT cover administration fees. Patients may still have out-of-pocket costs for the monthly injection visit at infusion centers or physician offices.
• Program restrictions: Not available where prohibited by law. Alnylam reserves the right to modify or discontinue the program.

Alnylam Assist® Patient Assistance Program (PAP)

For uninsured patients who cannot afford Givlaari and meet specified financial criteria, the PAP provides Givlaari at no cost. As a prescriber, you should:

• Identify uninsured or underinsured patients at the time of prescribing
• Complete the Givlaari Start Form and note that the patient does not have insurance coverage
• Alnylam Assist® will assess income and financial eligibility and enroll the patient if they qualify

Contact Alnylam Assist® at 1-833-256-2748 for PAP eligibility specifics.

Alnylam Assist® Bridge Program

The Bridge Program is particularly critical for providers to understand and use proactively. It provides Givlaari at no cost to patients whose insurance coverage has been denied or is pending appeal. Given that initial prior authorization denial rates for specialty biologics can exceed 30%, and that AHP patients cannot safely miss doses, the Bridge Program is a frontline tool for preventing treatment gaps.

Best practice: When submitting a prior authorization for any new Givlaari patient, simultaneously enroll them in the Bridge Program so that there is no gap if the initial PA is denied or takes longer than expected.

Navigating Medicare Coverage for Givlaari

Medicare patients face a particularly challenging cost landscape because they are not eligible for Alnylam's Commercial Copay Program. However, several protections now exist:

• $2,000 Part D annual out-of-pocket cap: Starting in 2025, the Inflation Reduction Act capped Medicare Part D out-of-pocket spending at $2,000/year. For Givlaari patients, this means maximum out-of-pocket drug costs are capped — a significant improvement.
• Medicare Part B vs. Part D: Because Givlaari is administered by a healthcare professional, it may be covered under Medicare Part B (which covers physician-administered drugs) rather than Part D, depending on the administration setting. Part B typically has lower patient cost sharing (20% after deductible). Verify coverage pathway with your billing team.
• Extra Help (Low Income Subsidy): Medicare patients with low incomes may qualify for the Extra Help program, which reduces Part D premiums and cost sharing.

Appeals as a Cost-Saving Strategy

A denied prior authorization is not a final answer. Successful appeals restore coverage and eliminate the cost burden entirely. Your office's ability to file compelling, evidence-based appeals directly reduces your patients' costs. Key best practices:

• Read every denial reason carefully and address each one with clinical evidence in your appeal letter
• Request peer-to-peer review — physician-to-physician conversations have high success rates for specialty drug appeals
• If internal appeal fails, request external independent medical review through your state's insurance commissioner — success rates can be 50-70% for well-documented specialty drug appeals in many states

Additional Resources

Additional resources that may help your patients with Givlaari costs:

• American Porphyria Foundation (APF) — patient advocacy and resource referrals at porphyriafoundation.org
• NeedyMeds and RxAssist — national PAP database searches
• State pharmaceutical assistance programs — some states supplement federal coverage for rare disease medications
• Counterforce Health and similar advocacy organizations — specialize in insurance appeals for complex specialty medications like Givlaari

medfinder: Reducing Logistics Cost Burden

While financial assistance programs address drug costs, your patients also face significant time and logistical burdens navigating the specialty pharmacy system. medfinder for providers contacts specialty pharmacies and clinical sites on behalf of your patients to identify where Givlaari can be filled and administered — reducing phone-call burden on your staff and ensuring patients don't miss doses due to access logistics.

Share our patient-focused savings guide with your patients: How to Save Money on Givlaari in 2026.